Cheever et al., 2022 - Google Patents
Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumorsCheever et al., 2022
View HTML- Document ID
- 12376984693022936918
- Author
- Cheever A
- Townsend M
- O’Neill K
- Publication year
- Publication venue
- Cells
External Links
Snippet
Chimeric antigen receptor (CAR) T cells are an exciting advancement in cancer immunotherapy, with striking success in hematological cancers. However, in solid tumors, the unique immunosuppressive elements of the tumor microenvironment (TME) contribute to …
- 206010028980 Neoplasm 0 title abstract description 295
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cheever et al. | Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors | |
| Hosseinkhani et al. | Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? | |
| Vaish et al. | Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting | |
| Du et al. | NK cell therapy: a rising star in cancer treatment | |
| Raimondo et al. | Extracellular vesicles and tumor-immune escape: biological functions and clinical perspectives | |
| Buller et al. | Roles of NK cell receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in cancer | |
| Del Prete et al. | Functional role of dendritic cell subsets in cancer progression and clinical implications | |
| Seliger et al. | Immune therapy resistance and immune escape of tumors | |
| Buoncervello et al. | The janus face of tumor microenvironment targeted by immunotherapy | |
| Upadhyay et al. | Lymphoma: immune evasion strategies | |
| Shaik Fakiruddin et al. | Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour | |
| Rückert et al. | Combinations of radiotherapy with vaccination and immune checkpoint inhibition differently affect primary and abscopal tumor growth and the tumor microenvironment | |
| Loskog | Immunostimulatory gene therapy using oncolytic viruses as vehicles | |
| Toffoli et al. | Natural killer cells and anti-cancer therapies: reciprocal effects on immune function and therapeutic response | |
| Barsoumian et al. | High plus low dose radiation strategy in combination with TIGIT and PD1 blockade to promote systemic antitumor responses | |
| Jo et al. | Innovative CAR-T cell therapy for solid tumor; current duel between CAR-T spear and tumor shield | |
| Zhai et al. | Challenges of anti-mesothelin CAR-T-cell therapy | |
| Hao et al. | The role of T cell immunotherapy in acute myeloid leukemia | |
| Hattori et al. | Natural killer immunotherapy for minimal residual disease eradication following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia | |
| Tripodi et al. | Oncolytic adenoviruses for cancer therapy | |
| Chung et al. | Emerging approaches for solid tumor treatment using CAR-T cell therapy | |
| Vu et al. | Cancer resistance to immunotherapy: molecular mechanisms and tackling strategies | |
| Lin et al. | Breast cancer tumor microenvironment and molecular aberrations hijack tumoricidal immunity | |
| Katiyar et al. | Cellular therapy for lung cancer: focusing on Chimeric Antigen Receptor T (CAR T) cells and Tumor-Infiltrating Lymphocyte (TIL) therapy | |
| Chen et al. | Monocytes in tumorigenesis and tumor immunotherapy |